ISRCTN15654915 https://doi.org/10.1186/ISRCTN15654915

Yorkshire Collaborative Small Cell Lung Cancer Study

Submission date	Recruitment status	[ ] Prospectively registered
19/08/2002	No longer recruiting	[ ] Protocol
Registration date	**Overall study status**	[ ] Statistical analysis plan
19/08/2002	Completed	[ ] Results
Last Edited	**Condition category**	[ ] Individual participant data
24/10/2019	Cancer	[ ] Record updated in last year

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr - -

Contact details
UKCCCR Register Co-ordinator
MRC Clinical Trials Unit
222 Euston Road
London
United Kingdom
NW1 2DA

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers
TH/SMC

Study information

Scientific Title
Yorkshire Collaborative Small Cell Lung Cancer Study

Study objectives
Not provided at time of registration

Ethics approval required
Old ethics approval format

Ethics approval(s)
Not provided at time of registration

Study design
Randomised controlled trial

Primary study design
Interventional

Secondary study design
Randomised controlled trial

Study setting(s)
Not specified

Study type(s)
Not Specified

Participant information sheet

Health condition(s) or problem(s) studied
Lung (small cell)

Interventions
Good/moderate-prognosis patients: Patients receive chemotherapy with Ifosfamide, etoposide, mensa and vincristine (EIMV) for three courses. Patients with greater than 50% response are randomised to either:
1. Group A: No mandatory treatment, radiotherapy is optional.
2. Group B: Three further courses of EIMV chemotherapy plus optional radiotherapy.

Poor-prognosis patients: Chemotherapy is at the physicians discretion. If chemotherapy is chosen single agent etoposide or EIMV chemotherapy is recommended.

Intervention Type
Other

Phase
Not Specified

Primary outcome measure
Not provided at time of registration

Secondary outcome measures
Not provided at time of registration

Overall study start date
01/01/1994

Completion date
01/04/1995

Eligibility

Key inclusion criteria
1. Small cell lung cancer confirmed by histological or bronchial brush or aspirate cytology.
2. Aged <75 years
3. Normal renal and hepatic function
4. No evidence of brain metastases
5. No previous specific anti-cancer treatment for current disease
6. No other malignant disease, except basal cell carcinoma and in situ carcinoma of the cervix

Participant type(s)
Patient

Age group
Not Specified

Sex
Not Specified

Target number of participants
Not provided at time of registration

Key exclusion criteria
Not provided at time of registration

Date of first enrolment
01/01/1994

Date of final enrolment
01/04/1995

Locations

Countries of recruitment
England

United Kingdom

Study participating centre

UKCCCR Register Co-ordinator
London
United Kingdom
NW1 2DA

Sponsor information

Organisation
Northern and Yorkshire Clinical Trials and Research Unit (UK)

Sponsor details
-
Leeds
United Kingdom
-

Sponsor type
Research organisation

Funder(s)

Funder type
Research organisation

Funder Name
Northern & Yorkshire Clinical Trials & Research Unit (UK)

Results and Publications

Publication and dissemination plan
Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary
Not provided at time of registration